Progenics (PGNX) Reports Positive Interim Phase 2 Results for Novel HIV Therapy PRO 140

October 27, 2008 7:24 AM EDT

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced positive interim results from two separate phase 2 clinical trials of PRO 140 for the treatment of HIV infection. Both intravenous and subcutaneous forms of PRO 140, a novel viral-entry inhibitor, exhibited potent and prolonged activity as measured by reductions in plasma levels of virus in individuals with HIV infection. Interim results (based on the first 15 of 31 patients treated) from the study of intravenous PRO 140 were presented in Washington, D.C. today as a "late-breaker" poster at the joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA). In this study, a 2.17 log(10) mean maximum reduction in viral load was observed in patients treated intravenously with a single 10 mg/kg dose, and the antiviral response persisted for three weeks post-treatment. Progenics Pharmaceuticals separately announced positive interim results (based on the first 20 of 44 patients treated) from the first clinical trial of subcutaneous PRO 140. In this study, the mean maximum viral load reduction was 1.77 log(10) for patients treated subcutaneously with three weekly doses of 324 mg PRO 140, and the antiviral response persisted for two weeks after the last dose. Both intravenous and subcutaneous forms of PRO 140 were generally well tolerated in these studies.

Subscribe to EasyStockAlerts.com Now & Get The News Before Everyone Else!

Related Categories

Corporate News
FDA

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?